Skip to main content

Table 3 Adjusted change in disease activity and PROs among first-line ADA and JAKi initiators at 6 and 12 months of follow-up relative to ETN

From: Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry

Outcome

At 6 monthsa

At 12 monthsb

ADA initiators

JAKi initiators

ADA initiators

JAKi initiators

CDAI

–0.08 (–1.48, 1.33)

–0.65 (–2.45, 1.15)

0.05 (–1.59, 1.69)

0.22 (–1.83, 2.27)

TJC-28

–0.08 (–0.82, 0.66)

–0.49 (–1.43, 0.46)

–0.17 (–1.06, 0.73)

–0.16 (–1.28, 0.96)

SJC-28

0.09 (–0.50, 0.69)

0.09 (–0.67, 0.86)

0.20 (–0.48, 0.88)

–0.21 (–1.06, 0.65)

PhGA

0.10 (–2.79, 2.99)

–1.04 (–4.74, 2.66)

–0.36 (–3.95, 3.24)

0.59 (–3.90, 5.08)

PtGA

0.01 (–3.69, 3.71)

–2.99 (–7.75, 1.77)

1.41 (–3.07, 5.89)

0.02 (–5.58, 5.62)

mHAQ

–0.01 (–0.07, 0.04)

–0.07 (–0.14, 0.00)

–0.03 (–0.10, 0.03)

–0.08 (–0.17, 0.00)

Patient pain

0.09 (–3.88, 4.06)

–1.10 (–6.21, 4.00)

2.71 (–2.16, 7.58)

0.33 (–5.79, 6.44)

Patient fatigue

–3.09 (–6.96, 0.78)

1.44 (–3.52, 6.39)

–0.13 (–5.00, 4.75)

4.26 (–1.82, 10.34)

EQ-5D

0.00 (–0.02, 0.02)

–0.01 (–0.04, 0.02)

–0.02 (–0.05, 0.01)

–0.01 (–0.05, 0.02)

Morning stiffness hours

–0.26 (–0.77, 0.25)

–0.26 (–0.92, 0.40)

0.21 (–0.40, 0.83)

–0.10 (–0.88, 0.68)

Achievement of LDA,c OR (95% CI)

1.09 (0.73, 1.62)

0.74 (0.44, 1.24)

0.90 (0.55, 1.47)

0.83 (0.45, 1.52)

Achievement of remission,d OR (95% CI)

1.13 (0.73, 1.74)

0.77 (0.41, 1.43)

0.96 (0.57, 1.63)

0.88 (0.44, 1.75)

Achievement of MCID in CDAI,e OR (95% CI)

1.10 (0.81, 1.50)

0.65 (0.43, 0.98)

1.01 (0.71, 1.45)

1.25 (0.79, 1.97)

  1. Values represent regression coefficients and 95% CIs, unless otherwise specified. A positive value for adjusted change indicates a larger degree of improvement relative to the ETN reference
  2. aAdjusted by baseline covariates including age, gender, rheumatoid factor positive status, college education, work status, private insurance, Medicare status, weight, history of comorbidities (CVD, hypertension, malignancy, serious infections, osteoporosis, and fractures), history of csDMARDs used, current therapy monotherapy or combination therapy, and CDAI
  3. bAdjusted by baseline covariates including age, gender, cyclic citrullinated peptide positive status, race (Black), college education, work status, private insurance, Medicare status, smoking status, weight, history of comorbidities (hypertension, malignancy, serious infections, osteoporosis, and fractures), history of csDMARDs used, current prednisone use, current therapy (monotherapy or combination therapy), and CDAI
  4. cCDAI score ≤ 10 among those with moderate or high disease activity at baseline
  5. dCDAI score ≤ 2.8 among those with low disease activity or more severe disease activity
  6. eMCID was defined as a decrease in CDAI score of > 1, > 6, and > 12 for those in LDA (CDAI ≤ 10), MDA (CDAI > 10–22), and HDA (CDAI > 22) at baseline, respectively
  7. ADA Adalimumab, CDAI Clinical Disease Activity Index, CI Confidence interval, csDMARD Conventional synthetic disease-modifying antirheumatic drug, CVD Cardiovascular disease, EQ-5D EuroQol-5D, ETN Etanercept, JAKi Janus kinase inhibitor, LDA Low disease activity, MCID Minimum clinically important difference, mHAQ Modified Health Assessment Questionnaire, OR Odds ratio, PhGA Physician’s Global Assessment of Disease Activity, PRO Patient-reported outcome, PtGA Patient’s Global Assessment of Disease Activity, SJC-28 Swollen joint count of 28 joints, TJC-28 Tender joint count of 28 joints
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us